|
1
|
Kawamura-Saito M, Yamazaki Y, Kaneko K,
Kawaguchi N, Kanda H, Mukai H, Gotoh T, Motoi T, Fukayama M,
Aburatani H, et al: Fusion between CIC and DUX4 up-regulates PEA3
family genes in Ewing-like sarcomas with t(4;19)(q35;q13)
translocation. Hum Mol Genet. 15:2125–2137. 2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Puls F, Niblett A, Marland G, Gaston CL,
Douis H, Mangham DC, Sumathi VP and Kindblom LG: BCOR-CCNB3
(Ewing-like) sarcoma: A clinicopathologic analysis of 10 cases, in
comparison with conventional Ewing sarcoma. Am J Surg Pathol.
38:1307–1318. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Haidar A, Arekapudi S, DeMattia F, Abu-Isa
E and Kraut M: High-grade undifferentiated small round cell sarcoma
with t(4;19)(q35;q13.1) CIC-DUX4 fusion: Emerging entities of soft
tissue tumors with unique histopathologic features-a case report
and literature review. Am J Case Rep. 16:87–94. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yoshimoto T, Tanaka M, Homme M, Yamazaki
Y, Takazawa Y, Antonescu CR and Nakamura T: CIC-DUX4 induces small
round cell sarcomas distinct from ewing sarcoma. Cancer Res.
77:2927–2937. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kao YC, Owosho AA, Sung YS, Zhang L,
Fujisawa Y, Lee JC, Wexler L, Argani P, Swanson D, Dickson BC, et
al: BCOR-CCNB3 fusion positive sarcomas: A clinicopathologic and
molecular analysis of 36 cases with comparison to morphologic
spectrum and clinical behavior of other round cell sarcomas. Am J
Surg Pathol. 42:604–615. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Antonescu CR, Owosho AA, Zhang L, Chen S,
Deniz K, Huryn JM, Kao YC, Huang SC, Singer S, Tap W, et al:
Sarcomas with CIC-rearrangements are a distinct pathologic entity
with aggressive outcome: A clinicopathologic and molecular study of
115 cases. Am J Surg Pathol. 41:941–949. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Endo M, Sugawara M, Yoshida A, Kobayashi
E, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Tamura K, Toki S,
et al: 1173-CIC-rearranged sarcoma and BCOR-CCNB3 sarcoma: Clinical
characteristics and treatment results of the newly-established
‘Ewing sarcoma-like’ small round cell sarcomas. Ann Oncol. 27
(Suppl 9):ix163–ix168. 2016.
|
|
8
|
Palmerini E, Gambarotti M, Ratan R, DuBois
S, Nathenson MJ, Italiano A, de Alava E, Jones RL, Provenzano S,
Grignani G, et al: Graceful Project: A global collaboration on
CIC-DUX4, BCOR-CCNB3, high grade undifferentiated round cell
sarcoma (URCS). In: Proceedings of the CTOS Annual Meeting, Tokyo,
Japan, 2019.
|
|
9
|
Brugieres L, Le Deley MC, Rosolen A,
Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A,
Marky I, et al: Impact of the methotrexate administration dose on
the need for intrathecal treatment in children and adolescents with
anaplastic large-cell lymphoma: Results of a randomized trial of
the EICNHL group. J Clin Oncol. 27:897–903. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fujita N, Kobayashi R, Takimoto T,
Nakagawa A, Ueda K and Horibe K: Results of the Japan association
of childhood leukemia study (JACLS) NHL-98 protocol for the
treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute
lymphoblastic leukemia in childhood. Leuk Lymphoma. 52:223–229.
2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bristow MR, Mason JW, Billingham ME and
Daniels JR: Doxorubicin cardiomyopathy: Evaluation by
phonocardiography, endomyocardial biopsy, and cardiac
catheterization. Ann Intern Med. 88:168–175. 1978.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Predina JD, Puc MM, Bergey MR, Sonnad SS,
Kucharczuk JC, Staddon A, Kaiser LR and Shrager JB: Improved
survival after pulmonary metastasectomy for soft tissue sarcoma. J
Thorac Oncol. 6:913–919. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Schur S, Hoetzenecker K, Lamm W, Koestler
WJ, Lang G, Amann G, Funovics P, Nemecek E, Noebauer I, Windhager
R, et al: Pulmonary metastasectomy for soft tissue sarcoma-report
from a dual institution experience at the Medical University of
Vienna. Eur J Cancer. 50:2289–2297. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yoshida A, Goto K, Kodaira M, Kobayashi E,
Kawamoto H, Mori T, Yoshimoto S, Endo O, Kodama N, Kushima R, et
al: CIC-rearranged sarcomas: A study of 20 cases and comparisons
with Ewing sarcomas. Am J Surg Pathol. 40:313–323. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Miser JS, Kinsella TJ, Triche TJ, Tsokos
M, Jarosinski P, Forquer R, Wesley R and Magrath I: Ifosfamide with
mesna uroprotection and etoposide: An effective regimen in the
treatment of recurrent sarcomas and other tumors of children and
young adults. J Clin Oncol. 5:1191–1198. 1987.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Minchom A, Jones RL, Fisher C, Al-Muderis
O, Ashley S, Scurr M, Karavasilis V and Judson IR: Clinical benefit
of second-line palliative chemotherapy in advanced soft-tissue
sarcoma. Sarcoma. 2010(264360)2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Leahy M, Garcia Del Muro X, Reichardt P,
Judson I, Staddon A, Verweij J, Baffoe-Bonnie A, Jönsson L, Musayev
A, Justo N, et al: Chemotherapy treatment patterns and clinical
outcomes in patients with metastatic soft tissue sarcoma. The
sarcoma treatment and Burden of Illness in North America and Europe
(SABINE) study. Ann Oncol. 23:2763–2770. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kawai A, Chuman H, Makimoto A, Ito Y,
Yamaguchi U, Morimoto Y and Beppu Y: Ifosfamide-etoposide
chemotherapy in patients with advanced adult soft tissue sarcomas.
J Clin Oncol. 22 (Suppl 14)(S9062)2004.
|
|
19
|
Grier HE, Krailo MD, Tarbell NJ, Link MP,
Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers
PA, et al: Addition of ifosfamide and etoposide to standard
chemotherapy for Ewing's sarcoma and primitive neuroectodermal
tumor of bone. N Engl J Med. 348:694–701. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Grohar PJ, Griffin LB, Yeung C, Chen QR,
Pommier Y, Khanna C, Khan J and Helman LJ: Ecteinascidin 743
interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Neoplasia. 13:145–153. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Forni C, Minuzzo M, Virdis E, Tamborini E,
Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, et al:
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma
tumors. Mol Cancer Ther. 8:449–457. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kawai A, Araki N, Sugiura H, Ueda T,
Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T,
et al: Trabectedin monotherapy after standard chemotherapy versus
best supportive care in patients with advanced,
translocation-related sarcoma: A randomised, open-label, phase 2
study. Lancet Oncol. 16:406–416. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Baruchel S, Pappo A, Krailo M, Baker KS,
Wu B, Villaluna D, Lee-Scott M, Adamson PC and Blaney SM: A phase 2
trial of trabectedin in children with recurrent rhabdomyosarcoma,
Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A
report from the children's oncology group. Eur J Cancer.
48:579–585. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Henderson TO, Whitton J, Stovall M,
Mertens AC, Mitby P, Friedman D, Strong LC, Hammond S, Neglia JP,
Meadows AT, et al: Secondary sarcomas in childhood cancer
survivors: A report from the childhood cancer survivor study. J
Natl Cancer Inst. 99:300–308. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ishida Y, Maeda M, Adachi S, Rikiishi T,
Sato M, Kawaguchi H, Manabe A, Tokuyama M, Hori H, Okamura J, et
al: Secondary bone/soft tissue sarcoma in childhood cancer
survivors: A nationwide hospital-based case-series study in Japan.
Jpn J Clin Oncol. 48:806–814. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wolpert F, Grotzer MA, Niggli F,
Zimmermann D, Rushing E and Bode-Lesniewska B: Ewing's sarcoma as a
second malignancy in long-term survivors of childhood hematologic
malignancies. Sarcoma. 2016(5043640)2016.PubMed/NCBI View Article : Google Scholar
|
